Trump Administration Streamlines Vape Approval Process for Charlie's

COSTA MESA, CA, Sept. 24, 2026 /CourierPR/ -- Charlie's Holdings (OTCQB: CHUC), an industry leader in the premium vapor products space, has applauded the Trump administration's recent plans to revise U.S. Food and Drug Administration (FDA) rules governing applications for new tobacco products. The administration is committed to keeping nicotine out of the hands of kids, getting counterfeit vaping products off the streets, and providing safer alternatives for adults who want to quit smoking cigarettes.

Charlie's Holdings has been actively pursuing FDA marketing authorization for its PACHA™ product line, which includes flavored vapes. Since September 2020, the company has been attempting to obtain FDA marketing authorization for certain of its tobacco-derived nicotine e-liquid products. Additionally, since May 2022, Charlie's has been working to secure FDA marketing authorization for hundreds of synthetic nicotine products, which are subject to the same FDA rules as tobacco-derived nicotine products.

The unwieldy PMTA review process has caused significant challenges for small American businesses, as they have spent years and substantial amounts of money trying to comply with the FDA's tobacco product authorization process. Meanwhile, counterfeit vaping products have flooded American streets, posing a significant risk to public health. The Trump administration's new plans aim to streamline this process, making it easier and faster for products like Charlie's flavored vapes to win regulatory approval.

Charlie's Holdings, Inc., a subsidiary of Charlie's Chalk Dust, LLC, has developed an extensive portfolio of brand styles, flavor profiles, and innovative product formats. The company's commitment to regulatory compliance and youth access prevention is a key differentiator. As of 2025, Charlie's has already sold 16 PACHA™ brand PMTA products to one of the world's largest tobacco companies, retaining 678 timely-filed PMTA assets. The company believes that the streamlined pathway for FDA authorization of timely-filed PMTAs will make Charlie's PACHA product line one of the most valuable portfolios in the industry.

The Trump administration's plans are in line with Charlie's corporate mission, which is to provide adult smokers with better alternatives to combustible cigarettes. The administration's commitment to keeping nicotine out of the hands of kids and providing safer alternatives for adults who want to quit smoking cigarettes is a significant step forward in ensuring a safer and more regulated vaping industry.

Charlie's Holdings, Inc., an industry leader in the premium vapor products space, has welcomed the Trump administration's plans to streamline the FDA authorization process for flavored vapes. The company has been actively pursuing FDA marketing authorization for its PACHA™ product line, which includes flavored vapes, since September 2020. Since May 2022, Charlie's has also been working to secure FDA marketing authorization for hundreds of synthetic nicotine products, which are subject to the same FDA rules as tobacco-derived nicotine products. The administration's plans aim to make it easier and faster for products like Charlie's flavored vapes to win regulatory approval, aligning with the company's mission to provide adult smokers with better alternatives to combustible cigarettes.